Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | RXRB | P28702 | 2/20 | 0.40 |
| ▸ | RXRG | P48443 | 2/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 8/20 | 0.40 |
| ▸ | GCGR | P47871 | 4/20 | 0.39 |
| ▸ | GIPR | P48546 | 3/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5585646 | 0.93 | PTGER1 (0.48) | PTGER1MRGPRX4CYP2C9 | |
| SCHEMBL5585387 | 0.90 | NPSR1 (0.41) | RXRARXRBRXRGPTGER1ALOX5 | |
| SCHEMBL5585434 | 0.90 | GCGR (0.44) | RXRARXRBRXRGPTGER1GCGR | |
| SCHEMBL5585777 | 0.82 | PTGER1 (0.49) | PTGER1MRGPRX4CYP2C9 | |
| SCHEMBL5585493 | 0.81 | GCGR (0.54) | RXRARXRBRXRGPTGER1GCGR | |
| SCHEMBL5585513 | 0.81 | NPSR1 (0.41) | RXRARXRBRXRGGCGRGIPR | |
| SCHEMBL5585563 | 0.80 | PTGER1 (0.40) | RXRARXRBRXRGPTGER1MRGPRX4 | |
| SCHEMBL5585453 | 0.80 | MRGPRX4 (0.40) | PTGER1GCGRGIPRMRGPRX4CYP2C9 | |
| SCHEMBL5585435 | 0.79 | ALOX5 (0.42) | RXRARXRBRXRGPTGER1MRGPRX4 | |
| SCHEMBL5585282 | 0.78 | GCGR (0.46) | RXRARXRBRXRGPTGER1GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065196-A1 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1452530-A1 | AZOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065196-A1 | Azole compound and medicinal use thereof | PTPN7, PTPN1, PTPN5 | RXRA 582/4885RXRB 427/4885RXRG 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.